Is a lower-dose, subcutaneous contraceptive injectable containing depot medroxyprogesterone acetate likely to impact women’s risk of HIV?

Ähnliche Einträge

• Is the Injectable Contraceptive Depo-Medroxyprogesterone Acetate (DMPA-IM) Associated with an Increased Risk for HIV Acquisition? The Jury Is Still Out
  von: Hapgood, Janet P.
  Veröffentlicht: (2020)
• Introducing the subcutaneous depot medroxyprogesterone acetate injectable contraceptive via social marketing: lessons learned from Nigeria's private sector()
  von: Liu, Jenny, et al.
  Veröffentlicht: (2018)
• Expanding Access to Injectable Contraception: Results From Pilot Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in 4 African Countries
  von: Stout, Anna, et al.
  Veröffentlicht: (2018)
• Self-administration of subcutaneous depot medroxyprogesterone acetate by adolescent women
  von: Williams, Rebekah L., et al.
  Veröffentlicht: (2013)
• Update to U.S. Selected Practice Recommendations for Contraceptive Use: Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate
  von: Curtis, Kathryn M., et al.
  Veröffentlicht: (2021)